
CLS Q4 - Softer sales than expected during the quarter

Redeye provides an update following CLS's Q4 2024 report. The results came in softer than we expected, and we argue that the company has an important year ahead, proving it can increase its sales and decrease costs. We make minor downward changes to our 2025e sales estimate and adjust our capital raising assumptions, rendering an updated fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[CLS Q4 - Softer sales than expected during the quarter](#)